What is BPC-157?
BPC-157 stands for Body Protection Compound 157. It is a chain of exactly 15 amino acids — making it a pentadecapeptide — first isolated from human gastric (stomach) juice.[2] Despite its gut origins, researchers have studied it across a surprisingly wide range of tissues, from tendons and ligaments to the lining of the intestines and even the nervous system.[2] It is important to note that BPC-157 has not been approved by the FDA or any major global regulatory authority for use in humans, and all current evidence comes from preclinical (animal) research plus a very small number of early human pilot studies.[3] This page is for research and educational purposes only.
How BPC-157 Works
Think of BPC-157 like a renovation crew dispatcher. When tissue is damaged, your body sends out signals asking for repair workers — new blood vessels, collagen-laying fibroblasts, and anti-inflammatory messengers. BPC-157 appears to amplify those signals and speed up the whole process.
On a molecular level, research suggests BPC-157 activates key pathways involved in angiogenesis (building new blood vessels), particularly through VEGFR2 and the Akt-eNOS axis, which boosts nitric oxide production.[4] It also activates ERK1/2 signaling to support endothelial (blood vessel lining) and muscle repair, while dialing down inflammatory cytokines — the chemical signals that cause swelling and pain.[3] This combination is especially useful in tissues that already have poor blood supply, like tendons and ligaments, where healing is naturally slow.[1]
BPC-157 is processed in the liver and has a short half-life of less than 30 minutes in the body, after which it is cleared by the kidneys.[3]
What the Research Shows
The bulk of BPC-157 research has been conducted in small rodent models. A 2019 review from Loughborough University found that every single study on BPC-157 in musculoskeletal soft tissue — covering tendons, ligaments, and skeletal muscle — reported consistently positive and prompt healing effects.[1] The authors highlighted its particular promise for hypovascular tissues like tendons, which heal poorly on their own.[1]
A 2025 systematic review published in the HSS Journal analyzed 36 studies (35 preclinical, 1 clinical) from 1993 to 2024. It found that BPC-157 improved functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bone injury models in animals.[3] The one clinical study reviewed was a retrospective look at intra-articular (joint) injections for chronic knee pain — 7 out of 12 patients reported relief lasting more than six months after a single injection.[3]
A separate 2025 narrative review noted that only three pilot human studies exist, covering knee pain, interstitial cystitis, and intravenous pharmacokinetics — and none reported adverse effects, though the authors stressed these are far too small to draw firm conclusions.[4]
On the gastrointestinal side, a 2021 review in Frontiers in Pharmacology summarized how BPC-157 promotes wound healing across multiple tissue types simultaneously — including colocutaneous and gastrocutaneous fistulas in rat models — pointing to broad tissue-repair signaling.[5] A 2025 literature and patent review confirmed BPC-157's preclinical effectiveness in conditions like inflammatory bowel disease and tissue injury, while flagging that no comprehensive clinical trials have yet confirmed these benefits in humans.[2]
What BPC-157 Is Being Studied For
- Tendon and ligament repair — accelerating healing in poorly vascularized connective tissue[1]
- Muscle injury recovery — including injuries from direct trauma and systemic insults[1]
- Bone healing — improved outcomes in fracture models[3]
- Gastrointestinal protection — mucosal integrity, ulcer models, and inflammatory bowel conditions[2]
- Wound healing — skin wounds, burns, and diabetic ulcers in animal models[5]
- Joint pain — intra-articular injection research for knee pain[6]
- Nervous system and CNS disorders — early preclinical exploration[2]
How BPC-157 Is Dosed in Research
Dosing in animal research is typically calculated by body weight and then extrapolated for reference purposes. In the research context, common ranges studied include 250–500 mcg per day for tissue and tendon repair, 250–500 mcg twice daily for gastrointestinal applications, and 200–300 mcg per day for general recovery support — with study durations typically running two to six weeks depending on the application. For a full breakdown of these ranges and how to scale them, see the dosage chart on this page and use the calculator to work through weight-based reference calculations. Remember: these figures are drawn from preclinical research and are provided for educational reference only — not as guidance for human use.
Mixing and Storing BPC-157
BPC-157 for research is typically supplied as a lyophilized powder — a freeze-dried white or off-white solid sealed in a sterile vial. To use it in a research setting, it must be reconstituted, meaning the powder is dissolved in a liquid. Bacteriostatic water (sterile water with a small amount of benzyl alcohol to prevent microbial growth) is the standard choice, as it extends the shelf life of the solution once mixed.
The general process: inject the bacteriostatic water slowly down the inside wall of the vial — never shoot it directly onto the powder. Gently swirl (don't shake) until fully dissolved. The resulting solution should be clear and colorless. Before reconstitution, lyophilized BPC-157 should be stored in a freezer or refrigerator away from light. Once reconstituted, keep it refrigerated (2–8°C / 36–46°F) and use within 4 weeks for best stability. Always work in a clean environment and use sterile equipment. Discard any solution that appears cloudy or discolored.
Sources
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. — Cell and tissue research, 2019. PMID 30915550.
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. — Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999.
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. — HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949.
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. — Current reviews in musculoskeletal medicine, 2025. PMID 40789979.
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. — Frontiers in pharmacology, 2021. PMID 34267654.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. — Alternative therapies in health and medicine, 2021. PMID 34324435.